This information is for research and educational purposes only. No medical recommendations. Products are not approved for human use. For health questions, consult a doctor.

Lexicon

NAD+ IV

High-dose redox coenzyme as a slow infusion - in the research context for energy metabolism and longevity signaling pathways.

6 min read 11 sources

Vial with white powder and a black TPD label reading “NAD+ IV” on a white podium with a glowing blue rim, next to a 3D molecule of blue, white and golden spheres in a bright lab
Phase 1 · not approved

Summary

At a glance

Sources checked on 26 Oct 2026

No rise in plasma
2 hours

for that long infused NAD+ vanished from the blood at once, pilot study with a 6-hour infusion1

Pump function after 1 month
45.4 %

against 42.4% on placebo, 180 people with heart failure, 7 days of infusion7

Duration of an NAD+ infusion
97 min

slower than nicotinamide riboside (37 min) because of symptoms, clinic review8

Outcome studies on NAD+ infusions for ageing
0 studies

in a systematic review of 33 human studies up to October 20259

  • NAD+ is a coenzyme in every cell. It carries electrons in energy production and is consumed by enzymes such as the sirtuins, PARP and CD38.24
  • In skin and blood plasma the NAD+ level falls with age. In old animals restoring NAD+ improved health and lifespan in studies, in humans this is open.563
  • As an infusion NAD+ vanished from the plasma at once for the first 2 hours. Afterwards NAD+ and methylnicotinamide appeared in urine.1
  • In a randomised trial with 180 people with heart failure pump function after 7 days of NAD+ infusion and 1 month was 45.4 against 42.4 percent on placebo.7
  • A review found no outcome study on NAD+ infusions for ageing. The registry lists one phase 1 trial and there is no approval. Everything here is the state of research, not a recommendation.91011
Profile

Updated June 2026

Route
IV infusion

slow, diluted

Vial
1000 mg powder
Class
Redox coenzyme / sirtuin substrate
Evidence
preclinical strong

IV clinical thin

Sizes
1,000 mg

1 size in the shop

Contents 14 sections
  1. At a glance
  2. What is NAD+ IV?
  3. How it works
  4. What you need
  5. Application (IV)
  6. Dosing
  7. What the research shows
  8. Research status
  9. Side effects
  10. Storage
  11. Related compounds
  12. FAQ
  13. Glossary
  14. Sources

What is NAD+ IV?

NAD+ stands for nicotinamide adenine dinucleotide - a coenzyme present in every single cell of your body. It is not an exotic molecule but one of the most central tools of metabolism, period. NAD+ cycles constantly between its oxidized (NAD+) and reduced form (NADH), shuttling electrons through the major energy pathways: glycolysis, the citric acid cycle and the respiratory chain.

The IV variant here is high-dose - 1000 mg of freeze-dried powder per vial, meant to be dissolved and given as a slow intravenous infusion in the research context. The idea behind it: orally taken NAD+ is largely broken down in the digestive tract before it arrives. An infusion bypasses that path and brings the substance directly into the bloodstream.

NAD+ IV has become popular in the wellness and longevity space. Important and honest: the controlled clinical evidence for the IV form is thin. The molecule itself is exceptionally well researched, the intravenous application by contrast has barely been tested in randomized studies. If you want to read deeper into the fundamentals, see the separate NAD+ lexicon entry. This information is for research and educational purposes only. No medical recommendations.

Comparison

NAD+ in different forms

NAD+ and related products, as described in the TPD lexicon. Tap a card to open its entry.

How it works

NAD+ has two fundamentally different jobs. That is exactly what makes it so interesting.

First, as a redox coenzyme. In glycolysis, the citric acid cycle and at the mitochondrial respiratory chain, NAD+ picks up electrons and releases them again. Without enough NAD+, ATP production stalls - the cell cannot supply its energy efficiently. That is textbook biochemistry, not a speculative mechanism.

Second, as a substrate for NAD+-consuming enzymes. This is where the longevity angle sits. Sirtuins (especially SIRT1) are NAD+-dependent enzymes involved in gene regulation, DNA repair, mitochondrial function and the cellular stress response. PARPs (DNA repair) and CD38 also consume NAD+. Reviews describe that tissue NAD+ levels decline with age and that this drop is preclinically linked to numerous aging processes.

The logic of supplementation: raise NAD+ again so that sirtuins and repair enzymes have more substrate. In animal models this could be shown convincingly. In humans - and especially via the IV route - the evidence is considerably thinner.

Where it acts

Where NAD+ plays a role in studies

Tap a point or a card. Grey = observed, partly in animal studies.

  1. Heart

    Pump function after 1 month higher than on placebo (heart failure, infusion)7

    Observed in trials
  2. Blood plasma

    Infused NAD+ vanished from plasma at once for 2 hours, with age NAD+ falls there1

    Observed in trials
  3. Skin

    NAD+ falls with age, in men PARP activity rises at the same time5

    Observed in trials
  4. Kidney and urine

    More NAD+ and methylnicotinamide in urine after an infusion1

    Observed in trials

Known targets2

Compound CHEMBL1234613: three described targets, type of action on each card.

Sirtuin 1
Gene
SIRT1
UniProt
Q96EB6
ChEMBL
CHEMBL4506
Action
Needs NAD+ as a cosubstrate and consumes it
PARP1 (DNA repair)
Gene
PARP1
UniProt
P09874
ChEMBL
CHEMBL3105
Action
Consumes NAD+ when repairing DNA breaks
CD38
Gene
CD38
UniProt
P28907
ChEMBL
CHEMBL4660
Action
Breaks down NAD+
Large translucent glass mitochondrion with winding inner folds, small blue and white molecules floating in them
NAD+ drives energy production in the mitochondria. Symbolic image.

What you need

NAD+ IV is different from a subcutaneous peptide. It is not injected with an insulin syringe but diluted and slowly infused intravenously. That belongs in skilled hands - an IV infusion is not a home DIY setup.

  • The NAD+ vial with the freeze-dried powder (1000 mg)
  • Sterile solution to dissolve and dilute (e.g. sterile or bacteriostatic water, then further into a larger infusion carrier solution)
  • A sterile infusion set with the ability to set the flow rate slowly
  • Alcohol swabs for the vial cap and the puncture site
  • A sealable container for used needles

If you are not familiar with IV access: this is the kind of application where experience and sterile technique are decisive.

Vial with a black TPD label reading “NAD+ IV” and a vial of bacteriostatic water, next to them two insulin syringes with blue caps, two alcohol swabs and a sharps container with a blue lid
For the infusion you need a sterile infusion set and a carrier solution instead of the insulin syringes. Symbolic image.

Application (IV)

Dosing. Loading the dosing information …

Dosing

Dosing

Dosing, titration and syringe

Loading the dosing information …

  • Getting started and stepping up, drawn as a staircase
  • Units on the U-100 syringe for every step
  • How long one vial lasts

What the research shows

Two things need to be kept cleanly apart here: the basic research on NAD+ as a molecule (strong) and the clinical evidence for the IV application (thin).

On the biology: reviews paint a consistent picture. Covarrubias et al. (2020) describe how NAD+ influences energy metabolism, DNA repair, chromatin and senescence. They also describe how tissue levels fall with age. Imai & Guarente (2014) laid out the NAD+-sirtuin axis early as an aging-relevant mechanism. Rajman et al. (2018) summarize the in vivo evidence for NAD+-boosting molecules - much of it convincing in animal models, more open in humans.

On the IV route specifically: the most important human work is the pilot study by Grant et al. (2019). They infused NAD+ into healthy individuals over 6 hours and tracked plasma and urine metabolites. Surprisingly: in the first 2 hours there was hardly any change in plasma NAD+ - the infused NAD+ was apparently removed from the plasma very quickly and completely and metabolized. Only later did metabolites and excretion products appear. That is a pure pharmacokinetic description, not a proof of efficacy.

Controlled studies demonstrating a clinical benefit of NAD+ IV for anti-aging or wellness endpoints are largely missing. That is the honest state: strong mechanistic foundation, popular practice, but thin outcome evidence specifically for the infusion.

Study results

What the trials measured

Interactive: switch tabs, tap points, show or hide arms. Arms are named relative to each other, no dosing advice.

NAD+ in heart failure after infarctions7

180 adults, 7 days of NAD+ or placebo into a vein on top of standard care

Pump function (LVEF)7 after 1 month
Placebo 42.4%
NAD+ as an infusion 45.4%
Better exercise capacity (NYHA)7 after 1 month, not significant
Placebo 57.3%
NAD+ as an infusion 73.0%
Major cardiovascular events7 over 6 months, not significant
Placebo 24.7%
NAD+ as an infusion 14.6%
First unplanned hospital admission7 for heart failure, 6 months, not significant
Placebo 23.6%
NAD+ as an infusion 13.5%

Abstract values 45.44 and 42.44 percent, rounded in the chart. Only pump function differed significantly. One hospital in China, registered in the Chinese trial registry. A study on disease, not on ageing.

How long an infusion took8

Mean minutes, review of client records of one clinic, four days each

Infusion time8
NAD+ as an infusion 97 min
Nicotinamide riboside as an infusion (comparison) 37 min

On NAD+ participants reported moderate to severe gastrointestinal symptoms, a faster pulse and chest pressure, so the infusion ran slower. All symptoms ended with the infusion. Retrospective review, the authors worked for the provider.

Large frosted glass model of a mitochondrion glowing warmly from within on a white lab bench between racks of sample tubes
Much research on precursors and animals, few studies with NAD+ as an infusion. Symbolic image.

Research status

Where the research stands

Registered trials with NAD+ as an injection or infusion. Precursors such as nicotinamide riboside and NMN as well as NAD+ taken orally, as a patch or a nasal spray are not included. The heart failure trial is in the Chinese registry and is therefore missing here. As of 26 Oct 2026. 10

  1. Preclinical Animal models of NAD+ in ageing
  2. Phase 1 1 trial, 0 completed
  3. Phase 2 no registered trial
  4. Phase 3 no registered trial
  5. Approval not yet
Not approved: ChEMBL lists NAD+ (nadide) with phase 2 as the highest phase, without an approval year.10
Show all 1 trial on a timelineHide timeline 0 completed 1 running 0 with results
Without phase

Bar: start to primary endpoint (planned for running trials). Green = completed, blue = progress until 26 Oct 2026. Phase 1: 1 trial on safety and pharmacokinetics, not shown as bars.

Side effects

By far the most common observation is pace-dependent: if the infusion runs too fast, flush (heat, redness), pressure in the chest or head, tightness, nausea, abdominal cramps or a general feeling of being unwell appear. These reactions typically ease once you slow the pace down - the reason the infusion should run slowly.

As with any intravenous application, the generic IV risks come on top: pain or irritation at the puncture site, plus an infection risk with poor technique. Sterile technique is not optional here.

Honest on the data: because controlled long-term studies on the IV form are missing, the full side-effect profile under repeated use is not well characterized. What is known is mainly the acute, pace-dependent effects.

Tolerability

Events in the heart failure trial

Out of 100 participants per group, how many had the event over 6 months.

1 of 100 Placebo
2 of 100 NAD+ as an infusion
Event PlaceboNAD+ as an infusion
Heart attack7 1%2%
Cardiac death7 1%1%
Stroke7 0%1%
Dizziness during infusion7 0%1%

Values from the full text (table 3 and safety section), none of the differences was significant. On placebo there was one case of chest discomfort. Liver and kidney values did not change. In a clinic review NAD+ infusions led to gastrointestinal symptoms, a faster pulse and chest pressure.78

Storage

Store the undissolved powder cool and dark. Once mixed, it keeps for at least 4 to 6 months in the fridge (2 to 8 °C). Only prepare the diluted infusion solution shortly before the infusion and use it promptly.

Shelf life

How long it keeps

Undissolved (powder) Cool and dark

Keep the undissolved powder cool and away from light.

Dissolved (mixed) Fridge, 2 to 8 degrees

Keeps for at least 4 to 6 months. Only prepare the diluted infusion solution shortly before the infusion.

  • Keep it dark
  • Dissolved: 2 to 8 degrees
  • Note the mixing date on the vial
Nine vials with white powder and blue caps in the door shelf of a bright fridge
Powder cool and dark, once dissolved into the fridge (2 to 8 degrees), stable there for at least 4 to 6 months. Symbolic image.

Related

Related compounds

Same targets, blends with NAD+ IV or a different path: all in the TPD lexicon.

FAQ

Common questions about NAD+ IV

Short answers, each backed by the sources below.

What is NAD+ and what does it do in the cell?

NAD+ is a coenzyme for redox reactions and therefore central to energy production. It is also fuel for enzymes such as the sirtuins, CD38 and PARP that take part in DNA repair, gene regulation and immune function. According to reviews NAD+ levels fall with age in rodent and human tissues.24

What happens to NAD+ given as an infusion into a vein?

In a pilot study with a 6-hour infusion plasma NAD+ did not rise at all in the first 2 hours, it was removed from the blood immediately and completely. Only after that did NAD+ and breakdown products rise. NAD+ itself and methylnicotinamide appeared in urine. The pattern fits breakdown by enzymes in the blood.1

Are there controlled trials with NAD+ as an infusion?

Few. The largest tested 180 adults with heart failure after infarctions: 7 days of NAD+ or placebo into a vein on top of standard care. After 1 month pump function was 45.4 against 42.4 percent, hospital admissions and major events were less frequent but not significantly. For anti-ageing a review found no outcome study with NAD+ as an infusion.79

Why do NAD+ infusions run so slowly?

Because of the symptoms. In a clinic review people on NAD+ reported moderate to severe gastrointestinal symptoms, a faster pulse and chest pressure. The infusion therefore took 97 minutes on average, with nicotinamide riboside 37 minutes. All symptoms ended with the infusion.8

Which side effects were seen in studies?

In the heart failure trial there was one case of dizziness on NAD+ that faded after about an hour. Heart attacks, strokes and deaths were rare in both groups and did not differ. Liver and kidney values were unchanged. Long-term data on repeated infusions are missing.79

What do animal studies and studies with precursors show?

In old or diseased animals restoring NAD+ improved health and lifespan in many studies. In humans the precursors NR and NMN reliably raised blood NAD+ levels, effects on health outcomes were inconsistent. Precursors taken by mouth are not the same as NAD+ in a vein.39

Glossary

Terms explained briefly

Dotted words in the text open these explanations directly.

CD38
Enzyme on immune and other cells that breaks down NAD+.
Coenzyme
Helper molecule that assists enzymes and is changed or consumed in the process.
Infusion
Slow delivery of a fluid directly into a vein, usually by drip.
Mitochondria
Power plants of the cell. Their respiratory chain produces most of the energy carrier ATP.
NMN and NR
Nicotinamide mononucleotide and nicotinamide riboside, precursors from which the body makes NAD+.
PARP
Enzymes that detect DNA breaks and consume NAD+ for the repair.
Placebo
Dummy preparation without active substance. Comparing against it shows what is due to the substance itself.
Pump function (LVEF)
Share of blood the left ventricle ejects per beat. It is reduced in heart failure.
Redox reaction
Chemical reaction in which electrons pass from one molecule to another. This is how the cell gains energy.
Sirtuins
Family of seven enzymes (SIRT1 to 7) that consume NAD+ and control genes and metabolism.

Evidence

Sources

Show all 11 sourcesHide sources 9 Studies1 Trial registry1 Database checked 26 Oct 2026

Studies

  1. Pilot study: NAD+ as a 6-hour infusion

    Grant et al., Frontiers in Aging Neuroscience, 2019

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  2. Review: NAD+ metabolism and ageing

    Covarrubias et al., Nature Reviews Molecular Cell Biology, 2021

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  3. Review: NAD-boosting molecules in animal studies

    Rajman, Chwalek und Sinclair, Cell Metabolism, 2018

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  4. Review: NAD+ and sirtuins in ageing

    Imai und Guarente, Trends in Cell Biology, 2014

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  5. NAD+ and PARP in human skin by age

    Massudi et al., PLoS One, 2012

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  6. NAD+ in blood plasma by age

    Clement et al., Rejuvenation Research, 2019

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  7. NAD+ infusion in heart failure, randomised against placebo

    Yu et al., American Journal of Cardiovascular Drugs, 2026

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed, PMC (Volltext)
  8. Tolerability of NAD+ and NR infusions in a clinic

    Reyna et al., Frontiers in Aging, 2026

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  9. Systematic review: NAD+ for anti-ageing

    Gallagher und Emmanuel, Ageing Research Reviews, 2026

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed

Trial registry

  1. Search on ClinicalTrials.gov

    ClinicalTrials.gov, U.S. National Library of Medicine

    Checked 26 Oct 2026 via ClinicalTrials.gov API v2

Database

  1. NAD+ (nadide) in ChEMBL

    ChEMBL, EMBL-EBI (CHEMBL1234613)

    Checked 26 Oct 2026 via ChEMBL

In the shop

NAD+ IV in the catalog

Sizes, prices and shipping times are on the product page.

To the product